Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Radiother Oncol. 2017 Oct 18;126(3):450–464. doi: 10.1016/j.radonc.2017.09.043

Fig. 3.

Fig. 3

The potential synthetic lethality interactions with ATR/CHK1 inhibitions. See text for description. The defect in the second pathway is presented by gray arrows.